New prescription treatment allows Canadians to manage acne better
Number one prescribed topical acne medication in the U.S. is now available in Canada
THORNHILL, ON, May 9 /CNW/ - Galderma Canada today announced Canadians now have access to a new once-a-day combination topical acne treatment designed to help people with mild to moderate acne. Tactuo™ is the first prescription topical acne gel to combine adapalene (0.1 per cent) with benzoyl peroxide (2.5 per cent). When used together, the two ingredients work effectively to unplug blocked oil glands and eliminate acne-causing bacteria, providing fast and visible results as early as the first week of use1. Tactuo™ can now be prescribed for patients who suffer from acne.
"Acne can be a very tough experience to deal with because it is highly visible for sufferers and caused by a multitude of factors. Patients often become frustrated with multiple treatments to rid their blemishes," says Jerry Tan, MD, FRCPC, Adjunct Professor, Schulich School of Medicine and Dentistry, University of Western Ontario. "Tactuo™ allows patients to manage acne with one combined treatment, giving them the ability to concentrate on their lives instead of their skin. We are thrilled that Canadian patients now have access to this novel product."
Acne affects more than five million Canadians2, with 80 per cent of those between the ages of 12 and 243. Although acne is most commonly seen as a stage of puberty, it can also begin in adulthood, with 75 per cent of adult acne occurring in women4.
Tactuo™ offers acne patients an easy-to-apply combination gel, which requires only one application per day before bed time. In most countries, Tactuo™ is marketed under the name Epiduo™, and it is already the number one prescribed topical acne medication in the U.S. The availability of Tactuo™ in Canada reinforces Galderma's ongoing commitment to the future of dermatology by providing innovative treatment options for patients.
Acne affects millions of Canadians, and it is a common myth that it will disappear without the use of any medication. "If left untreated acne can worsen, leaving unwanted scars on an individual's skin," says François Fournier, President, North America, Galderma Laboratories, L.P. "As the worldwide industry leader in the field of dermatology, our goal at Galderma is to make Canadians aware that individualized treatment approaches to the management of acne are available."
A Tactuo™ clinical trial published in 2007 in the Journal of the American Academy of Dermatology demonstrated that Tactuo™ reduced the median number of total acne lesions by more than 50 per cent at the end of the 12-week study, which was significantly better than monotherapy with either adapalene (35.4 per cent median reduction in total lesion count) or benzoyl peroxide (35.6 per cent median reduction in total lesion count) alone.5
"The need for an effective once-a-day acne treatment was clear given the prevalence of acne among Canadians and the absence of a similar combination therapy," says Wendy Adams, General Manager of Galderma Canada Inc. "We believe that as in the U.S. and other countries, Tactuo™ will become the product of choice for acne patients. This is a unique, effective combination, which provides quick, visible results that are sustained over time. It's an exciting time for Canadian acne patients and Galderma Canada."
Tactuo™ is now available for prescription and at pharmacies across Canada. Patients should speak with their family doctor or dermatologist to learn more about Tactuo™ and its suitability for their skincare needs.
Galderma Canada Inc. is a pharmaceutical company specializing in research and marketing of therapeutic, corrective and aesthetic solutions for dermatology patients. Our expertise spans a broad spectrum of skin and hair diseases. Our growing portfolio includes treatments for skin conditions such as acne, rosacea, psoriasis, eczema, skin cancers, and seborrheic dermatitis.
Galderma Canada Inc. was established in 1989 as an affiliate of Galderma, a global pharmaceutical company. Today, with a staff of 42, half of which is located in Thornhill, Ontario, we service more than 3,500 physicians in Canada with a special focus on dermatology.
1 Gollnick HPM, et al. Adapalene-BPO Study Group. Adapalene-benzoyl peroxide, a unique fixed-dose combination topical gel for the treatment of acne vulgaris: a transatlantic, randomized, double-blind, controlled study in 1670 patients. Br J Dermatol. 2009;161(5):1180-1189
2 Canadian Dermatology Association. Acne Brochure: Quick facts about acne. P. 2 http://www.dermatology.ca/acne/Acne-Brochure_e.pdf
3 Canadian Dermatology Association. Acne Brochure: Quick facts about acne. P. 2 http://www.dermatology.ca/acne/Acne-Brochure_e.pdf
4 Canadian Dermatology Association. Acne Brochure: Quick facts about acne. P. 2 http://www.dermatology.ca/acne/Acne-Brochure_e.pdf
5 Adapalene-benzoyl peroxide, a fixed-dose combination for the treatment of acne vulgaris: Results of a multicentre, randomized double-blind, controlled study. Thiboutot et al. Journal of the American Academy of Dermatology. Page 795. Volume 57, Number 5. 2007.
or to schedule an interview, please contact:
Kerry Collings, Argyle Communications
416-968-7311 ext 227